Today, leaders in the pharma space are in the midst of an unprecedented shift in operations. Although this was true even before COVID-19, the pandemic and the ensuing economic downturn have brought about a sea change in the way organizations look ahead in the future. In the present scenario, companies are up against a fresh set of hurdles even as the crisis has spurred technological innovations to support core objectives. As these challenges continue to disrupt the industry, it has also increased partnerships to develop new drugs. That said, companies are exploring opportunities to work together to streamline the drug development processes, which could lead to the emergence of new business models. Syneos Health is a fully integrated biopharmaceutical solutions organization that includes a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), which are purpose-built to accelerate a client’s performance in addressing modern market realities. Established through the merger of two industry-leading companies – INC Research and inVentiv Health – it brings together approximately 25,000 clinical and commercial experts with the ability to support customers in more than 110 countries.
Syneos Health offers a custom method development, assay validation, and sample analysis using state-of-the-art LC/MS/MS and immunochemistry assays. The company’s team of detail-oriented scientists has developed LC/MS/MS methods, including routinely quantifying levels below one pg/mL. “Syneos Health’s bioanalytical services center around delivering on our commitment to meet project schedules without compromising quality and compliance,” - Alistair Macdonald, CEO of Syneos Health. The firm recognizes.
the market need for fast turnaround, method development, and proof-of-concept, enabling companies to make quick go/no-go decisions. It offers a unique “full capability” approach to bioanalytical services, regardless of project size.
Syneos Health provides bioanalytical services at all stages of drug development through GLP-compliant laboratories, an extensive list of validated assays, custom assay services, knowledgeable scientists, and skilled technicians. The company has a long history of partnering with biopharmaceutical companies for in vivo, non-regulated preclinical bioanalysis of plasma and tissue samples. Syneos Health’s in-house expertise and access to a sophisticated array of modern instrumentation enable it to provide rapid turnaround times for clients.
The company’s development process is standardized around a robotics platform, which allows for improved precision, better reproducibility, and fewer errors. It offers protein binding, bioavailability, early toxicology, method qualification services for the target compound, and its metabolites. “We combine our significant experience with innovative science and efficient validated processes,” - Alistair Macdonald, CEO of Syneos Health.Soon, Syneos Health aims to help change the way biopharma products get to market. “We know that collaboration with our colleagues and customers unlocks creativity, innovation and new solutions,” - Alistair Macdonald, CEO of Syneos Health. The company focuses on leveraging its expertise and experience to partner, side-by-side, with leaders in the biopharma space to help transform health experiences. Driven by how its insights and solutions can impact people worldwide, Syneso Health has a passion for patients, which fuels its vision to shorten the distance from lab to life.
-
“Syneos Health’s bioanalytical services center around delivering on our commitment to meet project schedules without compromising quality and compliance,” - Alistair Macdonald, CEO of Syneos Health.
The company’s development process is standardized around a robotics platform, which allows for improved precision, better reproducibility, and fewer errors. It offers protein binding, bioavailability, early toxicology, method qualification services for the target compound, and its metabolites. “We combine our significant experience with innovative science and efficient validated processes,” - Alistair Macdonald, CEO of Syneos Health.Soon, Syneos Health aims to help change the way biopharma products get to market. “We know that collaboration with our colleagues and customers unlocks creativity, innovation and new solutions,” - Alistair Macdonald, CEO of Syneos Health. The company focuses on leveraging its expertise and experience to partner, side-by-side, with leaders in the biopharma space to help transform health experiences. Driven by how its insights and solutions can impact people worldwide, Syneso Health has a passion for patients, which fuels its vision to shorten the distance from lab to life.
